CClinicalTrials.gg
CompletedNCT00000211Updated Jan 12, 2017

Treatment Efficacy for Drug Abuse and AIDS Prevention - 2

A Phase 2 interventional study of Buprenorphine in Cocaine-Related Disorders and Heroin Dependence, sponsored by National Institute on Drug Abuse (NIDA). Completed at 1 site in United States. Open to male participants aged 26 Years to 41 Years. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by National Institute on Drug Abuse (NIDA) · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
0
Ages
26 Years to 41 Years
Sex
Male
01

Study summary

The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.

02

Conditions studied

  • Cocaine-Related Disorders
  • Heroin Dependence
03

Who can participate

Ages eligible
26 Years to 41 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Please contact site for information.

04

Study design

Phase
Phase 2
Primary purpose
Treatment
Enrollment
0 participants

Interventions

  • DrugBuprenorphine
05

Study locations

1 site
  • McLean Hospital, Dept. of Psychiatry
    Belmont, Massachusetts 2178, United States
06

Registry details

Key details

Study ID
NCT00000211
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
Mclean Hospital
Responsible party
Sponsor
First posted
Sep 21, 1999
Start date
Sep 1989
Primary completion
Feb 1996
Completion
Feb 1996
Last update
Jan 12, 2017

Study contacts

Jack Mendelson, M.D.
principal investigator · Mclean Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2002. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion